The U.S. authorized a third Covid-19 vaccine dose for people the most at risk; broader use is likely in rich countries. Pfizer will benefit, as will Moderna even if its $160 billion valuation counts on its selling more than just boosters, rob_cyran says.
The U.S. Food and Drug Administration on Aug. 12 authorized booster shots of existing Covid-19 vaccines made by Pfizer and Moderna for patients with compromised immune systems. The FDA amended the emergency use authorizations for the vaccines to allow third doses for “solid organ transplant recipients or those who are diagnosed with conditions that are considered to have an equivalent level of immunocompromise.
Rochelle Walensky, director of the Centers for Disease Control and Prevention, has said this group represents less than 3% of American adults. Other countries are studying or have authorized booster shots more widely. On Aug. 12, an advisory panel to Israel’s government recommended the country lower the age at which Israelis would be eligible to receive a booster shot to 50. In July, Israel began giving booster shots to people over 60.
The World Health Organization has asked governments to hold off on booster shots until more people worldwide receive their initial doses.A healthcare worker administers a shot of the Moderna COVID-19 Vaccine to a woman at a pop-up vaccination site operated by SOMOS Community Care during the coronavirus disease pandemic in Manhattan in New York City, New York, U.S., January 29, 2021.
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Pfizer, Moderna seen reaping billions from COVID-19 vaccine booster marketDrugmakers Pfizer Inc, BioNTech and Moderna Inc are expected to reap billions of dollars from COVID-19 booster shots in a market that could rival the $6 billion in annual sales for flu vaccines for years to come, analysts and healthcare investors say.
Read more »
Booster jabs are easy money for Pfizer and ModernaModerna (MRNA.O) and Pfizer (PFE.N) just found an additional pot of gold. The U.S. Food and Drug Administration on Thursday authorized a third dose of their coronavirus vaccines for immunocompromised people. That’s about 3% of Americans, but broader use is probably coming soon. Both companies will benefit, but Moderna’s roughly $160 billion market capitalization depends on it more.
Read more »
Booster jabs are easy money for Pfizer and ModernaModerna (MRNA.O) and Pfizer (PFE.N) just found an additional pot of gold. The U.S. Food and Drug Administration on Thursday authorized a third dose of their coronavirus vaccines for immunocompromised people. That’s about 3% of Americans, but broader use is probably coming soon. Both companies will benefit, but Moderna’s roughly $160 billion market capitalization depends on it more.
Read more »
FDA Authorizes Booster Shot for Immunocompromised AmericansThe third, or booster, dose of either Pfizer or Moderna vaccines would go to organ transplant patients, cancer patients and those with certain autoimmune diseases.
Read more »
Pfizer, Moderna seen reaping billions from COVID-19 vaccine booster marketDrugmakers Pfizer Inc, BioNTech and Moderna Inc are expected to reap billions of dollars from COVID-19 booster shots in a market that could rival the $6 billion in annual sales for flu vaccines for years to come, analysts and healthcare investors say.
Read more »